330793-73-2 Usage
Uses
Used in Organic Synthesis:
2-Benzoxazolamine, N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]is used as a building block for the synthesis of novel organic molecules. Its boron-containing phenyl group allows for cross-coupling reactions, enabling the formation of new chemical bonds and the creation of complex organic structures.
Used in Materials Science:
2-Benzoxazolamine, N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]is used as a component in the development of new materials. The stability provided by the tetramethyl-1,3,2-dioxaborolan-2-yl group allows for its incorporation into various materials, potentially enhancing their properties and performance.
Used in Pharmaceutical Industry:
2-Benzoxazolamine, N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]can be used as a starting material for the synthesis of pharmaceutical compounds. Its unique structure and reactivity make it a promising candidate for the development of new drugs and therapeutic agents.
Used in Chemical Research:
2-Benzoxazolamine, N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]is used as a research tool in chemical studies. Its ability to participate in various chemical reactions and its potential for cross-coupling make it a valuable compound for exploring new reaction pathways and understanding the fundamentals of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 330793-73-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,0,7,9 and 3 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 330793-73:
(8*3)+(7*3)+(6*0)+(5*7)+(4*9)+(3*3)+(2*7)+(1*3)=142
142 % 10 = 2
So 330793-73-2 is a valid CAS Registry Number.
330793-73-2Relevant academic research and scientific papers
Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases
Wang, Gary T.,Mantei, Robert A.,Hubbard, Robert D.,Wilsbacher, Julie L.,Zhang, Qian,Tucker, Lora,Hu, Xiaoming,Kovar, Peter,Johnson, Eric F.,Osterling, Donald J.,Bouska, Jennifer,Wang, Jieyi,Davidsen, Steven K.,Bell, Randy L.,Sheppard, George S.
scheme or table, p. 6067 - 6071 (2010/11/18)
This Letter describes the lead discovery, optimization, and biological characterization of a series of substituted 4-amino-1H-pyrazolo[3,4-d] pyrimidines as potent inhibitors of IGF1R, EGFR, and ErbB2. The leading compound 11 showed an IGF1R IC50 of 12 nM, an EGFR (L858R) IC50 of 31 nM, and an ErbB2 IC50 of 11 nM, potent activity in cellular functional and anti-proliferation assays, as well as activity in an in vivo pharmacodynamic assay.
Pyrazolopyrimidines as therapeutic agents
-
, (2008/06/13)
The present invention is directed to pyrazolopyrimidine derivatives of formula (I) wherein the substituents are defined herein, which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.
Pyrazolopyrimidines as therapeutic agents
-
, (2008/06/13)
The present invention provides compounds of Formula I, including pharmaceutically acceptable salts and/or prodrugs thereof, where G, R2, and R3 are defined as described herein.
